Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

BACKGROUND: Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study was designed to evaluate activity and safety of nab-paclitaxel in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelsomino, Francesco, Tiseo, Marcello, Barbieri, Fausto, Riccardi, Ferdinando, Cavanna, Luigi, Frassoldati, Antonio, Delmonte, Angelo, Longo, Lucia, Dazzi, Claudio, Cinieri, Saverio, Colantonio, Ida, Sperandi, Francesca, Lamberti, Giuseppe, Brocchi, Stefano, Tofani, Lorenzo, Boni, Luca, Ardizzoni, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341887/
https://www.ncbi.nlm.nih.gov/pubmed/32346071
http://dx.doi.org/10.1038/s41416-020-0845-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341887/
https://www.ncbi.nlm.nih.gov/pubmed/32346071
http://dx.doi.org/10.1038/s41416-020-0845-3

Ejemplares similares